These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 31316780)

  • 1. Efficacy and safety of infliximab in very early onset inflammatory bowel disease: a national comparative retrospective study.
    Bramuzzo M; Arrigo S; Romano C; Filardi MC; Lionetti P; Agrusti A; Dipasquale V; Paci M; Zuin G; Aloi M; Strisciuglio C; Miele E; Pastore M; Martelossi S; Alvisi P;
    United European Gastroenterol J; 2019 Jul; 7(6):759-766. PubMed ID: 31316780
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Infliximab for very early-onset inflammatory bowel disease: A tertiary center experience in Japan.
    Takeuchi I; Kaburaki Y; Arai K; Shimizu H; Hirano Y; Nagata S; Shimizu T
    J Gastroenterol Hepatol; 2020 Apr; 35(4):593-600. PubMed ID: 31425641
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Unique Disease Course of Children with Very Early onset-Inflammatory Bowel Disease.
    Kelsen JR; Conrad MA; Dawany N; Patel T; Shraim R; Merz A; Maurer K; Sullivan KE; Devoto M
    Inflamm Bowel Dis; 2020 May; 26(6):909-918. PubMed ID: 31560377
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incidence and Phenotype at Diagnosis of Very-early-onset Compared with Later-onset Paediatric Inflammatory Bowel Disease: A Population-based Study [1988-2011].
    Bequet E; Sarter H; Fumery M; Vasseur F; Armengol-Debeir L; Pariente B; Ley D; Spyckerelle C; Coevoet H; Laberenne JE; Peyrin-Biroulet L; Savoye G; Turck D; Gower-Rousseau C;
    J Crohns Colitis; 2017 May; 11(5):519-526. PubMed ID: 28453757
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Higher Prevalence of Monogenic Cause Among Very Early Onset Inflammatory Bowel Disease in Children: Experience From a Tertiary Care Center From Northern India.
    Poddar U; Aggarwal A; Jayalakshmi K; Sarma MS; Srivastava A; Rawat A; Yachha SK
    Inflamm Bowel Dis; 2023 Oct; 29(10):1572-1578. PubMed ID: 36594920
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Course of Very Early-Onset Inflammatory Bowel Disease.
    Cucinotta U; Arrigo S; Dipasquale V; Gramaglia SMC; Laganà F; Romano C; Gandullia P
    J Pediatr Gastroenterol Nutr; 2023 May; 76(5):590-595. PubMed ID: 36754082
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical course and outcomes of diagnosing Inflammatory Bowel Disease in children 10 years and under: retrospective cohort study from two tertiary centres in the United Kingdom and in Italy.
    Gasparetto M; Guariso G; Pozza LV; Ross A; Heuschkel R; Zilbauer M
    BMC Gastroenterol; 2016 Mar; 16():35. PubMed ID: 26976427
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Very Early Onset Inflammatory Bowel Disease: A Clinical Approach With a Focus on the Role of Genetics and Underlying Immune Deficiencies.
    Ouahed J; Spencer E; Kotlarz D; Shouval DS; Kowalik M; Peng K; Field M; Grushkin-Lerner L; Pai SY; Bousvaros A; Cho J; Argmann C; Schadt E; Mcgovern DPB; Mokry M; Nieuwenhuis E; Clevers H; Powrie F; Uhlig H; Klein C; Muise A; Dubinsky M; Snapper SB
    Inflamm Bowel Dis; 2020 May; 26(6):820-842. PubMed ID: 31833544
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and tolerability of initiating, or switching to, infliximab biosimilar CT-P13 in inflammatory bowel disease (IBD): a large single-centre experience.
    Ratnakumaran R; To N; Gracie DJ; Selinger CP; O'Connor A; Clark T; Carey N; Leigh K; Bourner L; Ford AC; Hamlin PJ
    Scand J Gastroenterol; 2018 Jun; 53(6):700-707. PubMed ID: 29687730
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Psoriasis and Psoriasiform Eruptions in Pediatric Patients with Inflammatory Bowel Disease Treated with Anti-Tumor Necrosis Factor Alpha Agents.
    Eickstaedt JB; Killpack L; Tung J; Davis D; Hand JL; Tollefson MM
    Pediatr Dermatol; 2017 May; 34(3):253-260. PubMed ID: 28211161
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nutritional Therapy in Very Early-Onset Inflammatory Bowel Disease: A Case Report.
    Miller TL; Lee D; Giefer M; Wahbeh G; Suskind DL
    Dig Dis Sci; 2017 Aug; 62(8):2196-2200. PubMed ID: 28551707
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Canakinumab for the treatment of autoinflammatory very early onset- inflammatory bowel disease.
    Shaul E; Conrad MA; Dawany N; Patel T; Canavan MC; Baccarella A; Weinbrom S; Aleynick D; Sullivan KE; Kelsen JR
    Front Immunol; 2022; 13():972114. PubMed ID: 36203564
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Loss of efficacy and safety of the switch from infliximab original to infliximab biosimilar (CT-P13) in patients with inflammatory bowel disease.
    Guerra Veloz MF; Argüelles-Arias F; Castro Laria L; Maldonado Pérez B; Benítez Roldan A; Perea Amarillo R; Merino Bohórquez V; Calleja MA; Caunedo Álvarez Á; Vilches Arenas Á
    World J Gastroenterol; 2018 Dec; 24(46):5288-5296. PubMed ID: 30581277
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased Discontinuation Rates of Anti-TNF Therapy in Elderly Inflammatory Bowel Disease Patients.
    de Jong ME; Smits LJT; van Ruijven B; den Broeder N; Russel MGVM; Römkens TEH; West RL; Jansen JM; Hoentjen F
    J Crohns Colitis; 2020 Jul; 14(7):888-895. PubMed ID: 31974546
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systematic review with meta-analysis: the efficacy and safety of CT-P13, a biosimilar of anti-tumour necrosis factor-α agent (infliximab), in inflammatory bowel diseases.
    Komaki Y; Yamada A; Komaki F; Micic D; Ido A; Sakuraba A
    Aliment Pharmacol Ther; 2017 Apr; 45(8):1043-1057. PubMed ID: 28239873
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term Outcomes After Switching to CT-P13 in Pediatric-Onset Inflammatory Bowel Disease: A Single-Center Prospective Observational Study.
    Kang B; Lee Y; Lee K; Choi YO; Choe YH
    Inflamm Bowel Dis; 2018 Feb; 24(3):607-616. PubMed ID: 29390113
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and Effectiveness of Vedolizumab for the Treatment of Pediatric Patients with Very Early Onset Inflammatory Bowel Diseases.
    Fabiszewska S; Derda E; Szymanska E; Osiecki M; Kierkus J
    J Clin Med; 2021 Jul; 10(13):. PubMed ID: 34279480
    [No Abstract]   [Full Text] [Related]  

  • 18. Evolution after switching to biosimilar infliximab in inflammatory bowel disease patients in clinical remission.
    Guerrero Puente L; Iglesias Flores E; Benítez JM; Medina Medina R; Salgueiro Rodríguez I; Aguilar Melero P; Cárdenas Aranzana MJ; González Fernández R; Manzanares Martin B; García-Sánchez V
    Gastroenterol Hepatol; 2017 Nov; 40(9):595-604. PubMed ID: 28865888
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dynamics of the Stool Virome in Very Early-Onset Inflammatory Bowel Disease.
    Liang G; Conrad MA; Kelsen JR; Kessler LR; Breton J; Albenberg LG; Marakos S; Galgano A; Devas N; Erlichman J; Zhang H; Mattei L; Bittinger K; Baldassano RN; Bushman FD
    J Crohns Colitis; 2020 Nov; 14(11):1600-1610. PubMed ID: 32406906
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incidence, outcomes, and health services burden of very early onset inflammatory bowel disease.
    Benchimol EI; Mack DR; Nguyen GC; Snapper SB; Li W; Mojaverian N; Quach P; Muise AM
    Gastroenterology; 2014 Oct; 147(4):803-813.e7; quiz e14-5. PubMed ID: 24951840
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.